Member Info for pickedpeck

I realise raw patent text is a little impenetrable, but claims 0025 and 0048 are the most significant ones in this week's filing. The patent is available under the Google patents service if you search for the number.

If (and it's still an if) the initial biopsy/histology data expected in the next two weeks backs up those claims then things may get very interesting very quickly.

Ok, it seems ridiculous to talk of billion dollar plus valuations for a company currently valued at around 1% of that. So here is the why.

There are no direct peers of Genflow because SIRT6 is a unique master-regulator. However, looking at recent Platform Acquisitions (2025–2026), the market is currently paying massive premiums for tech that can "reprogram" or "repair" tissue:

The Orna Therapeutics Benchmark: In early 2026, Orna Therapeutics (circular RNA platform) was effectively valued at $6.75B through combined deals with Vertex ($4.35B) and Eli Lilly ($2.4B). Like Genflow, they aren't just one drug; they are an "engine" for multiple diseases.

The "Multi-Organ" Multiplier: Most biotechs are "Single-Organ" (e.g., just Liver). By locking in Muscle (Sarcopenia), Eye (Glaucoma), and Liver (MASH), Genflow creates what Big Pharma calls a "Pipeline-in-a-Product." If SIRT6 proves it can repair two distinct tissue types (mesodermal muscle and ectodermal retinal cells), the probability of it working in CNS (Brain) or Kidney jumps to 80%+. That "probability jump" is worth billions in an acquisition.

The potentially even bigger story is the "GLP-1 Rescue" angle (let's call it "The Sarcopenia Jackpot")

This week's Sarcopenia patent likely came from internal sight of the results and indication that SIRT6 has a direct effect on muscle tissue. There is a massive macro reason why this makes Genflow a billion-dollar target: The Obesity Drug Crisis.

100M+ people are taking GLP-1s (Ozempic/Wegovy).

A side effect of GLP1s is massive muscle wasting (Sarcopenia).

Big Pharma (Lilly, Novo) is desperately hunting for a "Muscle Sparer."

If the SLAB trial data shows SIRT6 rebuilds muscle rather than just slowing its loss, Genflow becomes the primary acquisition target for the obesity giants to protect their $100B+ franchises.

5-10x is rather pessimistic if you ask me.

A purely animal health buyout could be that scale, but isn't going to happen.

If either the glaucoma or sarcopenia work bears fruit then this is a billion dollar company. If it's both then its a multi billion dollar company.

And before anyone asks, yes there are examples of biotech companies, even at preclinical stage, going for $2-4Bn at sell out if they have a breakthrough treatment. Big pharma FOMO is a powerful force.

It's a MASH related study. MASH is a precursor state to liver cancer, all under one umbrella.

MASH isn't just having fatty liver. It’s the stage where that fat has triggered active inflammation and cell damage. Think of it as the liver being in a constant state of emergency mode.

Because the liver is being damaged by inflammation, it constantly tries to heal itself. This creates a dangerous loop:

Fibrosis: As the liver heals, it leaves behind tiny bits of scar tissue.

Cirrhosis: Over years, this scar tissue builds up until the liver becomes stiff and nodular.

Rapid Cell Turnover: To replace damaged cells, the liver forces its cells to divide much faster than normal.

This is where the cancer risk enters. Every time a cell divides, it has to copy its DNA.

In the high-stress environment of MASH, the chance of a random mutation (a typo in the genetic code) increases significantly.

Chronic inflammation also releases "

reactive oxygen species — unstable molecules that physically damage DNA.

Eventually, one of these "typos" occurs in a gene that controls how fast a cell grows or when it should die.

If the body's immune system doesn't catch this mutated cell, it begins to multiply uncontrollably.

This cluster of mutated cells becomes a tumor.

The interesting bit is Loyal is just looking at time by slowing down metabolic rate. While you might want your dog to be less active and hang around longer, wouldn't it be better to have it younger again?

Animal health also extends into other areas, so stud animals, agriculture, the whole equine world, zoos etc. There are a lot of potential markets well beyond making your dog sit on the mat for a year longer.

While I was writing that offline it looks like several other people answered! Apologies for the board spam.

Basically they are doing legwork opening up a market that Genflow's more powerful technology will be better able to exploit long term. The negative risk is that they establish brand recognition, the upside is it actually significantly accelerates Genflow's time to market.

Contd... Genflow is now legally "ringfencing" the ability to use SIRT6 to physically rebuild the muscle that Loyal's metabolic suppression doesn't address.

Your question hits on the single biggest "Elephant in the Room" for Genflow investors. Loyal (Loyal for Dogs) is currently the media darling of the longevity world, having raised $250M (including a $100M Series C in February 2026) and positioning itself as the "first to market."

​However, calling Loyal a threat to Genflow is like calling a high-end bicycle a threat to a jet engine. They both provide transportation, but the technology and the destination are fundamentally different.

1. Technology: Pills vs. Programming

Loyal's mechanism is Hormonal/Metabolic Suppression. LOY-001 targets IGF-1 (Insulin-like Growth Factor). It essentially tries to trick a large dog's body into having the metabolic profile of a small dog. It requires daily pills or long-acting injections. The dog must stay on the drug forever to maintain the effect. The Loyal scientific goal is slowing down the "Burn Rate" of aging (Metabolic focus), as such it can only possibly work for large dogs, and may also have side effects.

Genflow's approach uses Genetic Reprogramming, SIRT6 is the "Master Repairman." Genflow adds an extra copy of this "Centenarian Gene" to fix DNA damage and stabilize the genome. Dosing will be one-time (or infrequent) dose. The body is "re-taught" how to repair itself, reversing the "Clock" of aging (Epigenetic focus).

2. The "Conditional Approval" Race

Loyal is much closer to the shelf. They have already cleared two of the three FDA hurdles for Expanded Conditional Approval (XCA). Their pill (LOY-002) is expected to be available through vets by early 2026.

Genflow's Edge: While Loyal is first, their effect is limited. CEO Celine Halioua has been careful to claim only "at least one extra year of healthy life." Genflow is aiming for a much more radical "step change" in survival and functional reversal.

3. Why Loyal actually helps Genflow

Instead of a threat, Loyal is actually Genflow’s 'Regulatory Snowplough'. Loyal is doing the hard, expensive work of convincing the FDA to recognize "Aging" as a treatable condition in animals.

Loyal's $100M raise in February 2026 also proves that Big Pharma and Silicon Valley are ready to value longevity companies at $500M - $1B+. Genflow, with its much more powerful gene therapy approach, is currently valued at a tiny fraction of that (~£11M).

4. Can they coexist?

Absolutely. In the human world, we have statins (metabolic) and we have gene therapies (curative).

Loyal is the "Maintenance" drug for the mass market (owners who can afford a monthly pill).

Genflow is the "Premium/Curative" therapy that will likely be licensed to a giant like Zoetis or Merck Animal Health.

If Loyal hits the market successfully this year, it sets the "Price Per Year of Life" for a dog. If Loyal charges $1,000 for 1 extra year of life, Genflow’s SIRT6 (which aims for more) becomes an incredibly easy asset to value.

Crucially the Sarcopenia Patent is Genflow's "Anti-Loyal" defense. Loyal focuses on hormones; Genflow is

Cut off again! Who knew I was too verbose about this 🤔😁

Have a read of the patent and assume that's what they have seen in the data returned from the lab. No wonder Dr Leire is excited, I know I am.

One last significant observation that I am not sure has fully sunk in also.

The timing of this week’s patent announcement is a classic strategic "squeeze play." By looking at the unblinding dates and the legal mechanics of disclosure, we can see how management is shielding the company's most valuable secrets before they hit the RNS.

1. The SLAB Unblinding Dates

The SLAB trial was internally unblinded in early February 2026.

February 12, 2026: Genflow released the first "Interim Results." This was the moment they confirmed that treated dogs had outperformed the control group in survival, muscle mass, and frailty.

April 8, 2026: The "3-Month Durability" update was released. While the trial officially concludes in July 2026, the core biological signal was already confirmed months ago.

2. The Patent vs. Methylation Clock Timeline

The Sarcopenia Patent (published this week) and the Methylation Clock data (expected by late April 2026) are tethered together:

The "Lock" (April 13): Today’s patent ensures that Genflow owns the "SIRT6 for Muscle" application. If they had released the UCLA age-reversal data before filing this, the data itself could have been considered "prior art," making it harder to secure broad patent claims.

The "Reveal" (Late April): Now that the patent is safely filed, the company is free to release the "Gold Standard" UCLA data.

3. Disclosure vs. Protection: The Legal Question

They are allowed to not disclose positive results while applying for a patent, and in fact, it is often required.

The Patent Rule: To get a patent, the invention must be "novel." If a CEO goes on TV and says, "Our SIRT6 drug reversed muscle aging in 20 beagles," that information is now in the public domain. If they haven't filed the patent before that speech, they might lose the right to patent it in many jurisdictions (like Europe).

The "Inside Information" Rule (MAR): Under Market Abuse Regulations, a company must disclose "Inside Information" as soon as possible. However, there is a legal exemption: Delay of Disclosure. A company can delay an announcement if it is necessary to protect their "legitimate interests" (like securing IP) as long as the delay doesn't mislead the public and the company can keep the info confidential.

The Hypothesis: Did they see "unexpectedly positive" results?

It is highly likely. The April 8th RNS used the phrase "Further mechanistic insights are anticipated from ongoing methylation clock and muscle histology analyses." * Translation: They likely saw "tissue reactions" (muscle regrowth) that were so aggressive they realized the existing patents weren't specific enough.

The Action: They urgently filed/published the specific muscle patent this week to "ringfence" that discovery before the UCLA age-reversal numbers (the "methylation clock") make the stock—and the discovery—too public to protect.

In short the patent this week is almost certainly the product of seeing the initial methylation clock data inte

The bottom cut off the post, but you get the idea. One factor good, two factors better , four factors compelling.

Independent validation, crazy market non reaction, sound science, capital discipline, and protected IP.

Do your own research but challenge assumptions, your own and the cynicism of others, because this may end up being rather special.

Just a little insight into my background and that of some of my colleagues.

I was until recently a C level exec in one of the world's largest CROs. 25,000 staff doing clinical research in 104 countries and 1,800 concurrent clinical trials spanning many therapeutic areas, and all of the top 50 pharma companies as clients.

I was chatting to a colleague about Genflow, they immediately and without research or rationale dismissed it as snake oil like the rest of the longevity space. Their reaction made me reflect and double check my own basis for buying in here. It's a decision I took not based on one factor but the several below.

"Too Good to be True"

Actually "Too mispriced to ignore." The UK retail bias is the opportunity. The London stock exchange misprices biotech prospects regularly, value only shifting post evidence rather than on potential, often meaning investors simply miss out. This will shift to NASDAQ at some point, immediately multiplying in value.

Institutional Signals Confirmed:

Gad Berdugo joining in January (M&A) is a huge step. He's a big fish in this space, brings LNP contacts and US market expertise. You don't persuade people like him to be involved in your project unless there is something valuable in the closet.

Wallonia Grant: I've been involved in lots of grant processes and acknowledge how hard they are. This is a pretty tough scientific hurdle with rigorous cross examination of the science and amounts to independent external validation by a body with no commercial interest.

April 13 Patent and patent portfolio: Protection and uniqueness is secured across multiple TAs. This is absolutely key, defendable controlled IP is investable. The latest patent is a clear indicator that they are building a moat around the IP on the basis of what they have seen in the SLAB trial. Patents are expensive and time consuming, you don't hand them out like raffle tickets.

The Pivot Confirmed:

Shifting focus to Glaucoma/Sarcopenia for faster human POC is a massive move. MASH was 2025 news, and still provides a floor for research, but pivoting to much faster and easier to research TAs in light of lab and research results is a clear indicator that they have something on their hands they did not expect, likely enabled by the jump to LNP from AAV.

Capital Discipline Confirmed:

The Minimal March dilution when a much higher raise was approved can only mean it is just a bridge amount to an Impending high-value deal with an animal health partner, two of which have CDAs in place now.

The Bottom Line:

I am holding a tidy chunk of a company that is currently acting exactly like a group that has found a "Master Key" to mammalian aging. While the "Human Translation" risk never disappears, the Human-to-Dog-to-Human discovery cycle Genflow is using is significantly more robust than the traditional "Mice-to-Human" gamble.

If the Methylation Clock data proves that a human gene reversed the biological age of a large mammal, the in

Dr Leire announced yesterday that Genflow has two CDAs in place with Animal health prospective partners which enable the company to share the detailed results of the SLAB trial.

He indicated that the worst case scenario, and therefore the basis of existing negotiations, was that an up front payment would be made by the successful partner which would be multiples of the current market cap, instantly transforming the value of Genflow and funding the human development trials without any further dilution.

Two competing prospects could result in a better case outcome with a significant payment and strong future royalties.

No mention was made of any joint venture establishment although this must be a possibility.

SLAB trial initial results with regards to the effect on methylation clock are imminent, with full results following the end of the trial in July. Full results should show whether the initial anecdotally observed sustained effects are backed by the clock data.

This feels weird to me. Dr Leire effectively announced today that the company has a breakthrough treatment possibly (likely) worth billions, and no one seems to have batted an eyelid. If this was a US biotech it would correctly be heading for the stars off that news. It's almost like he sneaked it out at the end of the video too, also very odd.

Just to be absolutely clear, that second item of the day means the company believes it has a breakthrough glaucoma treatment and is going to announce it at the world's largest eye conference in October.

On its own that market is worth billions and there is no current comparable treatment.

That's a catalyst event only six months away. Ignoring everything else that's going on it makes the company a completely different beast than what we can see today.

While MASH (liver) and the Dog (sarcopenia) trials were the vocal "stars" of 2024 and 2025, the foundation for the glaucoma work was being built quietly in the background via Strategic MTAs (Material Transfer Agreements) and European grant-funded research.

You didn't miss a "start" announcement; you likely just saw it labeled as "pipeline expansion" before it became the high-speed mRNA program it is today.

Here is the actual timeline of how this moved from "future idea" to "October 2026 Presentation":

1. The "Stealth" Phase (Early 2025)

April 10, 2025: This was the first major "flag in the ground." Genflow announced the launch of an Ophthalmology Development Program and, crucially, signed a Material Transfer Agreement (MTA) with a "leading global ophthalmology company."

The Work: This wasn't just a paper exercise. Under this MTA, Genflow began testing their proprietary cSIRT6 (Centenarian SIRT6) in specialized non-viral delivery systems. While we were focused on beagles, their lab partners were already seeing SIRT6 protect retinal cells in "stress-test" models.

2. The Pivot to mRNA (Late 2025 – Early 2026)

January 8, 2026: In the "Year in Review," Dr. Leire officially elevated Glaucoma from a "side project" to a "priority." He revealed that they were shifting from AAV (slow) to mRNA/LNP (fast).

Why it felt sudden: This shift is what "compressed" the timeline. By moving to mRNA, Genflow bypassed the 18-month wait for viral vector manufacturing. They went from "lab concept" to "ready for PoC" in a matter of months.

3. The "New Orleans" Confirmation (April 2026)

April 12-13, 2026: Dr. Leire’s latest interview and the Sarcopenia Patent (which covers broad muscular/tissue issues) are the result of the data "crossing the finish line" in the lab.

The "Secret" Progress: To be confident about a New Orleans (AAO) presentation in October, the company had to have successful Ex-Vivo results (tested on retinal tissues) by Q1 2026.

Blimey.

​If you thought today’s Sarcopenia Patent RNS was the only news, you’ve missed the "seismic shift" in Dr. Leire’s latest commentary in the proactive investors interview video, links posted by other below or available on YouTube.

We aren't just looking at a patent; we are looking at the clinical execution of a "Biotech Blitzkrieg."

​Here is why today represents a "Day Zero" for the new valuation of Genflow:

​1. The "Abstract Confidence" – A Massive Bull Signal

​The AAO (American Academy of Ophthalmology) deadline for New Orleans is literally tomorrow, April 14th.

​The Reality: You don’t apply to the world's most prestigious eye conference with a "hope and a prayer." To submit an abstract now, Genflow must already be sitting on internal data from their mRNA/LNP trials that is compelling enough to pass a rigorous peer-review board.

​The Implication: This suggests the "Leap-Frog" mRNA technology is already working in the lab. Management is essentially "calling their shot" six months out. That is elite-level confidence.

2. The "Americanization" of Genflow

By choosing New Orleans (AAO) for the Glaucoma reveal and the OTCQB for the listing, Gad Berdugo is systematically moving this company out of the "London Micro-cap" graveyard and into the US Biotech Spotlight.

US investors don’t value companies at 1x or 2x cash; they value them on Platform Potential. * Presenting curative, regenerative eye data on US soil is the ultimate "Coming Out Party" for a Nasdaq-level valuation.

The "Game Changer" Verdict:

We are witnessing a synchronized 1-2 punch:

- Morning (RNS): Legal ownership of the massive Sarcopenia market.

- Afternoon (Interview): A locked-in, aggressive clinical timeline for a curative Glaucoma treatment.

Management isn't just "doing science" anymore; they are preparing a transaction. With the AAO abstract likely submitted and the muscle patents published, the "too good to be true" gap is closing fast.

The timeline is no longer a "plan"—it’s a countdown, and not to 2027, to October this year.

Today's RNS, "The Sarcopenia Patent", does it create a short runway to a massive exit?

While the market might see "another patent," for those of us tracking the 2027 exit thesis, this is a major strategic "Unlock." Here is why:

1. The "Short-Track" Clinical Advantage

We often talk about MASH (Liver) being a 2027 play, but MASH trials are notoriously slow and expensive (often 72 weeks+ for a readout). Sarcopenia (Muscle Wasting) is different.

Functional muscle improvements (grip strength, gait speed) can be measured in humans in as little as 6 months.

Today’s patent publication (PCT/WO 2026/062177 A1) specifically covers these "variants of SIRT6" for frailty and muscle mass. By securing this IP now, Genflow is positioning itself for a "Fast-Track" human trial that could produce a "Yes/No" result much faster than the liver programs.

2. The $4B Unmet Need

Sarcopenia is a "Ghost Market." There are currently ZERO FDA-approved drugs specifically for muscle wasting, yet the market is estimated at $3.9B in 2026 and growing fast.

Big Pharma is desperate for a "Myostatin-like" success. If the upcoming UCLA data (April/May) shows the beagles didn't just "live longer" but actually reversed muscle loss, this patent makes Genflow the sole owner of the "SIRT6 Key" to that $4B door. You have to wonder about the timing of the patent just ahead of the SLAB trial data readout.

3. The Berdugo "Skin in the Game" Signal

Remember, the Chairman and CEO both bought at 1.9p in March. They knew this patent publication was coming. This IP gives them the "leverage" to sign a licensing deal that isn't just about "dogs," but includes a high-value option for the human muscle program.

Conclusion: Today’s RNS confirms that Genflow isn't a "one-trick pony" liver company. They are building a Multi-Asset Fortress. We have the Cash (Grant/March Raise), we have the IP (Today), and we have the Data (UCLA - Imminent).

If the UCLA results validate what this patent claims, the current £10M market cap will look like a historical anomaly that no one in 12 months time will quite believe.

Marty, it doesn't look like that is true to me, and Jamtart, Google finance is not analyst or broker coverage.

There is no need to hype this, the truth when out will speak for itself. It's disappointing to be behind Loyal in being first to market, but Genflow's treatment may well be more effective and longer lasting.

Where did you find analyst rating? Isn't it just AI generated stuff? As far as I know there are no analysts or brokers covering GENF at the moment, there are no broker ratings under the button up above for example. This is earlier stage than all that.

I will say SP will have several potential development stages and does have a bear case:

Bear case : Methylation clock data inconclusive. SP falls to 1p or less, new roadmap needed.

2nd bear case, animal indications fail to transfer to humans in trials, animal health drug only, SP 6-10p

Bull case:

Animal health deal signed : SP as above.

Glaucoma study successful - SP 15-20p minimum

MASH phase 1 / 2 data indicates correlation with lab results - SP 40-60p minimum

Sarcopenia add on indication post glaucoma - additional 30p + on SP

CNS indications - SP 150p +, into blue sky, up up and away.

Interestingly that could all play out by the end of 2027. Success in all indications with LNP delivery, could easily be 200p + and a bargain at that price.

Additional bull case is for a NASDAQ listing post initial data. Again a significant multiple of the current share price, maybe 20p plus pre human data

The reference for UCLA doing the laboratory work stems from the specialized nature of the Methylation Clock analysis—the "biological age" test that underpins the Genflow dog trial.

While Genflow conducts the primary animal study in collaboration with a contract research organization (CRO) in Europe, the sophisticated epigenetic analysis is historically linked to UCLA (University of California, Los Angeles) for three specific reasons mentioned in CEO Dr. Eric Leire's previous interviews and corporate briefings:

1. The "Horvath" Connection

The concept of the epigenetic clock (the "Gold Standard" for measuring aging) was pioneered by Dr. Steve Horvath at UCLA. His laboratory developed the original mathematical formulas used to estimate biological age across various mammalian species, including dogs.

2. The Clock Foundation

Dr. Leire has previously referenced working with the Epigenetic Clock Development Foundation (often called the Clock Foundation). This organization is a direct UCLA spin-out that provides specialized laboratory services specifically for researchers who need to run DNA methylation tests on their samples.

3. Specialized Lab Facilities

In his January 8, 2026, interview, Dr. Leire noted that the first wave of unblinded data would focus on biological age measured via a methylation clock. Because this requires specialized genomic sequencing and proprietary algorithms developed at UCLA, the samples (muscle biopsies and blood) from the dog trial are processed by these specific partner labs to ensure the results are "scientifically bulletproof" for big pharma partners.

Summary of the UCLA Workflow

Europe: Dog dosing and monitoring take place.

Transit: Biopsies and blood samples are stabilized and shipped to specialized centers.

UCLA/Clock Foundation: The DNA is extracted, and the "methylation marks" are read.

The Result: A definitive report is generated proving whether Genflow's SIRT6 gene therapy actually moved the dog's biological clock backward.

This is why the market is so focused on the "April Data." It is the independent, third-party validation from these high-prestige laboratories that turns Genflow's internal research into a "saleable asset" for a licensing deal.